Many of the deals are acquisitions of companies that are closer to their fair value where the premium may be 30-50% on average. That being said, larger premiums aren't that uncommon in the right circumstances.
There are many examples where the premium is well over 100% when the last traded price isn't close to the company's value. Merck paid a 160% premium to the 1-month VWAP for VLA on the ASX as one example.
https://accelerateshares.com/research/alpharank-merger-monitor-synergies-in-science-exploring-biotech-ma-dynamics/
"Biotech takeovers typically feature significant control premiums. Since 2020, the average biotech takeover premium was 87.5%, compared to the M&A universe average (ex-biotech) of 41.7%. In addition, takeover over premiums in the biotech sector can soar to truly astronomical levels, with seven deals featuring a takeover premium above 200%, two north of 300%, and one at a stunning 667% premium. Large takeover premiums are extremely rewarding to investors.
Many of the deals are acquisitions of companies that are closer...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.25 |
Change
0.070(0.53%) |
Mkt cap ! $1.698B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.41 | $13.12 | $2.327M | 175.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1012 | $13.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.27 | 517 | 13 |
View Market Depth
| Last trade - 13.55pm 10/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |